ARCHIVES

NCI advisors approve $50 million pilot for Human Cancer Genome Project; NHLBI Director Collins calls it a “unique, historic opportunity.”

This article is from The Cancer Letter archive.

Vol. 31 No. 42 | November 18, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: Panel Meeting Canceled; New Senior Executive Service Draws Enthusiastic Response At NCI

July 13, 1979

M.D. Anderson Must Evaluate 8 Patients In Controversial Study

May 31, 1996

The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken.

May 7, 2004

Guest Editorial: As Sequestration Becomes More Likely, Health Groups Must Make Themselves Heard

February 22, 2013

Advisors approve NCI’s revised plan for $104-million proteomics research program.

July 8, 2005

Authorization Bill Passes Senate 82-0

June 27, 1980